What we do Medicamen Organics Ltd develops, manufactures, and distributes a wide range of generic pharmaceutical dosages including tablets, capsules, syrups, and ointments primarily through contract manufacturing. |
Founded in 1,995 |
Market share Strong presence in Indian pharma contract manufacturing with expanding exports to Africa, CIS, and Southeast Asia markets. |
Problem solved Provides affordable generic medicines and pharma products for government and private sectors enhancing healthcare accessibility. |
Top clients or who we serve Government bodies, private institutions, and international distributors in B2B model covering Africa, CIS, and Southeast Asia. |
Key management - |
Our journey and innovations Founded in 1995, obtained WHO/GMP certification, expanded capacities, and directly entered international markets including Africa since 2023. |
Where we operate India, Africa (Burundi, Congo, Kenya, etc.), CIS, and Southeast Asian countries. |
Top products or what we offer Pharmaceutical generics: Anti-bacterial, Anti-diabetic, NSAIDs, multivitamins, and related dosage forms. |
Top brands - |
Raw materials needed Active Pharmaceutical Ingredients and excipients for generic drug manufacturing. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily recurring from contract manufacturing and export distribution. |
Our industry position Niche player in contract manufacturing with growing international presence and compliance certifications. |
Financial highlights FY 2024-25 consolidated revenue Rs 38.19 crore; net profit Rs 4.05 crore, showing significant year-on-year growth. |
Geographical revenue split Domestic India major portion; increasing exports to Africa and Southeast Asia contributing to revenue growth. |
Order book - |
Whats driving growth International market entry, expanded manufacturing capacity, strategic acquisitions, and regulatory certifications. |
Our future plans Scaling production capacity, product registrations abroad, subsidiary integration, and brand development in Africa and cosmetics globally. |
Our green promise - |
Our people and values - |
Key challenges ahead Competition in pharma generics, regulatory compliance, raw material sourcing, and expanding international reach. |
Interesting facts IPO in 2024 was oversubscribed 994 times; first exports to Burundi in 2023; formed subsidiaries for pharma and cosmetics. |
Risks and strategy Mitigating regulatory and market risks via certifications, diversification of markets, and subsidiary ecosystem. |
